Utah Cell Bank made unapproved injectable stem cell products and fell short on sterility and manufacturing controls, FDA found.
What happened
FDA inspected Utah Cord Bank (doing business as Utah Cell Bank) and FIOR Bioscience, which share a site in Sandy, Utah, from February 1 to February 11, 2021, and also reviewed the FIOR Bioscience website. Investigators found the company was selling injectable umbilical cord blood, cord and amniotic membrane products claimed to treat diseases, without an approved license (BLA) or a research permit (IND), and they listed 14 significant deviations from manufacturing quality rules. These included aseptic (sterile) processing that was never validated, an unclassified production area, a sterility test never validated, and 16 sterility failures from 2017 to 2020 that were never investigated.
What FDA found
The company never validated its sterile filling process with media fills, and staff wore non-sterile lab coats, gloves and hair nets while making products claimed to be sterile.
21 CFR 211.113(b)Products were made in an area with no air quality classification, more than one operator worked in the same space at once, and there was no environmental monitoring, personnel monitoring or validated cleaning.
21 CFR 211.42(c)(10)The company had no sound specifications or test methods, and released whole lots on the sterility result of only a few vials, even when lots ran to many vials.
21 CFR 211.160(b)Lot release rested on an in-house sterility test that was never validated, so records could not show the method was accurate and reliable.
21 CFR 211.194(a)(2)Sixteen sterility failures between July 2017 and January 2020 were not investigated for the contaminating organism, root cause, or effects on other lots; the failed lots were simply discarded.
21 CFR 211.192Two-to-six year expiration dates were assigned with no stability data to support them.
21 CFR 211.166(a)
What FDA wants
FDA asks the company to reply in writing within 15 working days describing the specific steps taken or planned to fix each violation and prevent recurrence, with supporting documents. If the company believes it is not in violation, it must send its reasoning and supporting information.
Who should pay attention
- clinics and physicians buying injectable stem cell or birth tissue products
- distributors and marketers of unapproved biologics
- labs and tissue banks doing aseptic processing of HCT/Ps
This is a summary. Read the original letter on fda.gov.